Mantle Cell Lymphoma International Prognostic Index (MIPI)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۵۰ — حداکثر ۱۰۰۰۰ • واحد: U/L
حداقل ۱۵۰ — حداکثر ۴۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۵۰۰ • واحد: ×10³/μL
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–5.7
- Intermediate Risk5.7–6.2
- High Risk6.2–20
The Mantle Cell Lymphoma International Prognostic Index (MIPI) calculator is designed for bedside predicting survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count in clinical practice. The resulting score directly guides clinician decision-making regarding initiating targeted.
Clinical Guidelines & Evidence
Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.
Clinical Indication
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is indicated for bedside clinical practice to support Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Most mantle cell lymphoma patients require treatment at diagnosis regardless of risk group.
MIPI = (0.03535 × age in years) + 0.6978 (if ECOG PS 2-4) + [1.367 × log10(LDH/ULN)] + [0.9393 × log10(WBC in ×10³/μL)]. MIPIb (biological MIPI) = MIPI + (0.02142 × Ki-67 index %) when Ki-67 is available.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years. Age is a continuous variable in the MIPI formula and significantly impacts prognosis(years) |
| ecog_performance_status | string | Yes | ECOG Performance Status scale measuring patient's functional status and ability to perform daily activities |
| serum_ldh | float | Yes | Serum lactate dehydrogenase level in U/L. Elevated LDH indicates tissue damage, cellular turnover, or disease burden(U/L) |
| ldh_upper_limit_normal | float | Yes | Laboratory's upper limit of normal for serum LDH in U/L. Typically ranges from 200-250 U/L depending on laboratory and methodology(U/L) |
| white_blood_cell_count | float | Yes | White blood cell count in cells per microliter (×10³/μL). Elevated WBC may indicate disease burden or bone marrow involvement(×10³/μL) |
| ki67_index | float | No | Ki-67 proliferation index as percentage (0-100%). Optional parameter for calculating biological MIPI (MIPIb). Higher Ki-67 indicates more aggressive disease(%) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–5.7 | Low Risk | Low risk for poor prognosis |
| 5.7–6.2 | Intermediate Risk | Intermediate risk for poor prognosis |
| 6.2–20 | High Risk | High risk for poor prognosis |
Evidence-Based References (EBM)
- Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. doi: 10.1182/blood-2007-06-095331.DOI: 10.1182/blood-2007-06-095331
- Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, Trneny M, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338-46. doi: 10.1200/JCO.2013.52.2466.DOI: 10.1200/JCO.2013.52.2466
- Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025.DOI: 10.1182/blood-2008-03-147025